- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03941236
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
April 5, 2024 updated by: Zealand Pharma
An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism
This is an open-label, multinational, multicenter, long-term safety and efficacy extension trial in patients with Congenital Hyperinsulinism (CHI) who completed either ZP4207-17103 or ZP4207-17109 (defined as lead-in trials).
The primary objective is to evaluate the long-term safety of dasiglucagon administered as subcutaneous (SC) infusion in children with CHI.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
44
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Düsseldorf, Germany, 40225
- University Hospital Düsseldorf, Department of Pediatrics
-
Magdeburg, Germany, 39120
- Otto von Guericke University Magdeburg, Department of Pediatrics
-
-
-
-
-
Jerusalem, Israel, 9765422
- Hadassah Medical Center
-
-
-
-
-
Glasgow, United Kingdom
- NHS Greater Glasgow and Clyde
-
Liverpool, United Kingdom
- Alder Hey Children's Hospital NHS Foundation Trust
-
London, United Kingdom
- Great Osmond Street Hospital for Children NHS Foundation Trust
-
Manchester, United Kingdom
- Central Manchester University Hospital NHS Foundation Trust
-
-
-
-
Colorado
-
Aurora, Colorado, United States, 13123
- Children's Hospital of Colorado
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Cook Children's Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 13 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Completed treatment in either Trial ZP4207-17103 or ZP4207-17109
- Expected to continue to have a positive benefit-risk assessment for treatment with dasiglucagon (based on considerations of glycemic effect, tolerability, and nature and frequency of adverse events experienced in the lead-in trial)
Exclusion Criteria:
- The patient developed any conditions prohibited by the lead-in trial, requires medication prohibited by the lead-in trial, or has other new complications that preclude participation in the investigator's opinion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dasiglucagon open-label
Dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
|
Glucagon analog
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: Baseline through treatment completion, up to 3 years
|
Number of adverse events occurring up to Month 1, Month 1 to Month 3 and in each 3-month period for the first year; subsequent years will have longer periods assigned for analysis
|
Baseline through treatment completion, up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of gastric carbohydrates administered to treat hypoglycemia
Time Frame: Baseline through treatment completion, up to 3 years
|
Total amount of gastric carbohydrates administered via nasogastric tube or gastrostomy per week to treat hypoglycemia
|
Baseline through treatment completion, up to 3 years
|
Nasogastric (NG) tube or gastrostomy removal
Time Frame: Baseline through treatment completion, up to 3 years
|
Time to removal of NG tube or gastrostomy
|
Baseline through treatment completion, up to 3 years
|
Pancreatic surgery
Time Frame: Baseline through treatment completion, up to 3 years
|
Time to pancreatic surgery (sub-total or total pancreatectomy)
|
Baseline through treatment completion, up to 3 years
|
Time in hypoglycemia
Time Frame: Baseline through treatment completion, up to 3 years
|
Continuous glucose monitoring (CGM) percent time <70 mg/dL (3.9 mmol/L)
|
Baseline through treatment completion, up to 3 years
|
Hypoglycemia episodes
Time Frame: Baseline through treatment completion, up to 3 years
|
Rate of CGM-detected hypoglycemia episodes <70 mg/dL (3.9 mmol/L) for 15 minutes or more
|
Baseline through treatment completion, up to 3 years
|
Clinically significant episodes of hypoglycemia
Time Frame: Baseline through treatment completion, up to 3 years
|
Rate of clinically significant CGM-detected hypoglycemia episodes <54 mg/dL (3.0 mmol/L) for 15 minutes or more
|
Baseline through treatment completion, up to 3 years
|
Gastric carbohydrate administrations
Time Frame: Baseline through treatment completion, up to 3 years
|
Number of gastric carbohydrate administrations (nasogastric tube or gastrostomy) to treat hypoglycemia
|
Baseline through treatment completion, up to 3 years
|
Nightly gastric carbohydrate administrations
Time Frame: Baseline through treatment completion, up to 3 years
|
Number of nightly (midnight to 6 am) gastric carbohydrate administrations (nasogastric tube or gastrostomy) to treat hypoglycemia
|
Baseline through treatment completion, up to 3 years
|
Extent of hypoglycemia
Time Frame: Baseline through treatment completion, up to 3 years
|
Extent of hypoglycemia (area over the glucose curve [AOCglucose] below 70 mg/dL [3.9 mmol/L]) as measured by continous glucose monitoring (CGM)
|
Baseline through treatment completion, up to 3 years
|
Extent of clinically significant hypoglycemia
Time Frame: Baseline through treatment completion, up to 3 years
|
Extent of hypoglycemia (area over the glucose curve [AOCglucose] below 54 mg/dL [3.0 mmol/L]) as measured by continous glucose monitoring (CGM)
|
Baseline through treatment completion, up to 3 years
|
Diazoxide dose
Time Frame: Baseline through treatment completion, up to 3 years
|
Reduction in diazoxide dose in mg/kg body weight/day from start of lead-in trial
|
Baseline through treatment completion, up to 3 years
|
Somatostatin analog dose
Time Frame: Baseline through treatment completion, up to 3 years
|
Reduction in somatostatin analog dose from start of lead-in trial
|
Baseline through treatment completion, up to 3 years
|
Prescribed amount of continuous gastric carbohydrate administration
Time Frame: Baseline through treatment completion, up to 3 years
|
Change in total amount of prescribed continuous gastric carbohydrate administration from start of lead-in trial (g/day)
|
Baseline through treatment completion, up to 3 years
|
Prescribed duration of continuous gastric carbohydrate administration
Time Frame: Baseline through treatment completion, up to 3 years
|
Change in prescribed duration of infusion of continuous gastric carbohydrate administration from start of lead-in trial (h/day)
|
Baseline through treatment completion, up to 3 years
|
Prescribed duration of nightly continuous gastric carbohydrate administration
Time Frame: Baseline through treatment completion, up to 3 years
|
Change in prescribed duration of infusion of nightly (8 pm - 8 am) continuous gastric carbohydrate administration from start of lead-in trial (h/day)
|
Baseline through treatment completion, up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Jelena Ivkovic, MD, Zealand Pharma
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2019
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
January 1, 2025
Study Registration Dates
First Submitted
May 2, 2019
First Submitted That Met QC Criteria
May 4, 2019
First Posted (Actual)
May 7, 2019
Study Record Updates
Last Update Posted (Actual)
April 8, 2024
Last Update Submitted That Met QC Criteria
April 5, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZP4207-17106
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Hyperinsulinism
-
University Medicine GreifswaldCompletedNon-focal Congenital HyperinsulinismGermany
-
Children's Hospital of PhiladelphiaUniversity of PennsylvaniaCompletedPersistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI) | Congenital Hyperinsulinism (CHI)United States
-
Beijing Children's HospitalCompletedCongenital Hyperinsulinaemic Hypoglycaemia | Octreotide Adverse ReactionChina
-
University Hospital, Basel, SwitzerlandGottfried und Julia Bangerter-Rhyner-StiftungRecruitingEndogenous HyperinsulinismSwitzerland
-
Miguel PampaloniRecruitingCongenital HyperinsulinismUnited States
-
Zealand PharmaCompletedCongenital HyperinsulinismUnited States, United Kingdom, Germany, Israel
-
Montefiore Medical CenterNo longer availableCongenital HyperinsulinismUnited States
-
Diva De LeonTerminatedCongenital HyperinsulinismUnited States
-
Diva De LeonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedCongenital HyperinsulinismUnited States
-
Assistance Publique - Hôpitaux de ParisNovartisCompleted
Clinical Trials on dasiglucagon
-
Zealand PharmaCompletedHypoglycemia | Diabetes Mellitus, Type 1United States
-
Zealand PharmaRecruiting
-
Zealand PharmaCompleted
-
Filip Krag KnopZealand PharmaActive, not recruitingHyperinsulinemic Hypoglycemia | Postprandial HypoglycemiaDenmark
-
Zealand PharmaWithdrawnGlucose Metabolism Disorders | Hypoglycemia
-
University Hospital, Gentofte, CopenhagenCompletedHyperinsulinemic Hypoglycemia | Postprandial HypoglycemiaDenmark
-
Zealand PharmaCompletedHypoglycemia | Diabetes Mellitus, Type 1Canada, United States, Austria, Germany
-
Zealand PharmaCompletedHypoglycemiaUnited States, Germany, Slovenia
-
Zealand PharmaCompletedCongenital HyperinsulinismUnited States, United Kingdom, Germany, Israel
-
Steno Diabetes Center CopenhagenCompletedHypoglycemia | Type 1 DiabetesDenmark